Salix Will Feature New Data At Digestive Disease Week® 2021
News provided by
Share this article
TRULANCE® (plecanatide) ePoster Will be Honored as Poster of Distinction
LAVAL, QC, May 17, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ) and its gastroenterology business, Salix Pharmaceuticals, ( Salix ), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced four scientific poster presentations featuring data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) to be shared at Digestive Disease Week® (DDW) 2021, which takes place virtually May 21-23, 2021. The posters will be accessible on DDW s ePosters and ePapers online portal beginning Friday, May 21, 2021.
Share this article
Share this article
LAVAL, QC, April 27, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced the Company is providing a presentation on its business during the Company s Annual Meeting of Shareholders on April 27, 2021. The presentation will be available on the Investor Relations section of the Bausch Health website. The Company has filed a Form 8-K this morning, annexing this presentation.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting
News provided by
Share this article
®, DUOBRII
®
LAVAL, Quebec, April 21, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of six posters during the virtual American Academy of Dermatology (AAD) Annual Meeting, which takes place April 23-25, 2021.
One presentation will feature new analyses of ARAZLO
® (tazarotene) Lotion, 0.045%, including new topline efficacy results from a post hoc analysis of two Phase 3 studies on participants with moderate-to-severe acne. Approved for patients nine years of age and older, ARAZLO has been commercially available since 2020. Two other presentations will highlight DUOBRII
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
News provided by
Share this article
Share this article
LAVAL, Quebec, April 7, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced it will reduce debt by $100 million through the redemption of outstanding senior secured notes, using cash generated from operations.
Bausch Health will redeem $100 million aggregate principal amount of its outstanding 7.00% Senior Secured Notes due 2024, CUSIP Nos. 91911K AK8, C94143 AK7 (the Notes ) on May 7, 2021. The Company previously redeemed a total of $200M aggregate principal amount of the Notes in March 2021.